Switch theme
Sign up to access all valuation multiples
Suven Pharmaceuticals Ltd is involved in developing and manufacturing intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology, and chemical companies. The company operates majorly in the Manufacturing (CRAMS) segment, which includes bulk drugs and intermediates under contract services. Its geographical segments include India, the USA, Europe, and the Rest of the World. The majority of the company's revenue comes from the Europe segment.
2018
1.1K+
LTM Revenue $252M
LTM EBITDA $85.0M
$3.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Suven Pharma has a last 12-month revenue of $252M and a last 12-month EBITDA of $85.0M.
In the most recent fiscal year, Suven Pharma achieved revenue of $120M and an EBITDA of $54.3M.
Suven Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Suven Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $155M | $120M | XXX | XXX | XXX |
| Gross Profit | $85.3M | $86.6M | XXX | XXX | XXX |
| Gross Margin | 55% | 72% | XXX | XXX | XXX |
| EBITDA | $71.2M | $54.3M | XXX | XXX | XXX |
| EBITDA Margin | 46% | 45% | XXX | XXX | XXX |
| Net Profit | $52.7M | $47.8M | XXX | XXX | XXX |
| Net Margin | 34% | 40% | XXX | XXX | XXX |
| Net Debt | $5.9M | $0.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Suven Pharma's stock price is INR 1150 (or $13).
Suven Pharma has current market cap of INR 293B (or $3.4B), and EV of INR 286B (or $3.3B).
See Suven Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.3B | $3.4B | XXX | XXX | XXX | XXX | $0.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Suven Pharma has market cap of $3.4B and EV of $3.3B.
Suven Pharma's trades at 13.2x LTM EV/Revenue multiple, and 39.1x LTM EBITDA.
Analysts estimate Suven Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Suven Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $3.3B | XXX | XXX | XXX |
| EV/Revenue | 15.5x | XXX | XXX | XXX |
| EV/EBITDA | 43.8x | XXX | XXX | XXX |
| P/E | 65.7x | XXX | XXX | XXX |
| P/E/Growth | 1.5x | XXX | XXX | XXX |
| EV/FCF | 2411.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSuven Pharma's NTM/LTM revenue growth is 57%
Suven Pharma's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $26K for the same period.
Over next 12 months, Suven Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Suven Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Suven Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -22% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -24% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 92% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $26K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 22% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Piramal Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Suven Pharma acquired XXX companies to date.
Last acquisition by Suven Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Suven Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Suven Pharma founded? | Suven Pharma was founded in 2018. |
| Where is Suven Pharma headquartered? | Suven Pharma is headquartered in India. |
| How many employees does Suven Pharma have? | As of today, Suven Pharma has 1.1K+ employees. |
| Is Suven Pharma publicy listed? | Yes, Suven Pharma is a public company listed on BOM. |
| What is the stock symbol of Suven Pharma? | Suven Pharma trades under 543064 ticker. |
| When did Suven Pharma go public? | Suven Pharma went public in 2020. |
| Who are competitors of Suven Pharma? | Similar companies to Suven Pharma include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Suven Pharma? | Suven Pharma's current market cap is $3.4B |
| What is the current revenue of Suven Pharma? | Suven Pharma's last 12-month revenue is $252M. |
| What is the current EBITDA of Suven Pharma? | Suven Pharma's last 12-month EBITDA is $85.0M. |
| What is the current EV/Revenue multiple of Suven Pharma? | Current revenue multiple of Suven Pharma is 13.2x. |
| What is the current EV/EBITDA multiple of Suven Pharma? | Current EBITDA multiple of Suven Pharma is 39.1x. |
| What is the current revenue growth of Suven Pharma? | Suven Pharma revenue growth between 2023 and 2024 was -22%. |
| Is Suven Pharma profitable? | Yes, Suven Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
